Podcasts Focus on Latest Neuromuscular Research

"This Month in Muscular Dystrophy" is the subject of a new audio series from Nationwide Children's Hospital in Columbus, Ohio

Article Highlights:
  • Doctors at the Neuromuscular Disorders Program at Nationwide Children’s Hospital in Columbus, Ohio, have begun a monthly series of podcasts focusing on the latest in muscle-disease research.
  • The series gives authors of recent publications an opportunity to discuss how their work improves understanding of inherited neuromuscular diseases, and what it might mean for treatment of these diseases. 
  • The podcasts are designed for patients, caregivers and families, as well as primary care physicians and other health professionals who want to keep abreast of muscle-disease research, yet may not have access to the latest literature.
by Miriam Davidson on May 24, 2010 - 3:53pm

Scientists at the Neuromuscular Disorders Program at Nationwide Children’s Hospital in Columbus, Ohio, are producing a series of podcasts examining current research in neuromuscular disease.

The series, “This Month in Muscular Dystrophy,” is an opportunity to hear authors of recent publications discuss how their work improves understanding of these diseases, and what it might mean for treatment.

The first two podcasts, posted in April and May, featured the work of two MDA-funded researchers at Nationwide, Jerry Mendell and Brian Kaspar. Mendell discussed his latest work on gene therapy for muscular dystrophy and Kaspar spoke about his work on gene therapy for spinal muscular atrophy (SMA).

The third podcast, to be posted in June, will feature Kate Bushby, a neuromuscular disease researcher at Newcastle University in England, who also is a former MDA grantee. She will discuss standards of care in Duchenne muscular dystrophy.

Two goals

Kevin Flanigan

“We have a couple of goals with these podcasts,” said series host Kevin Flanigan, a physician at the Nationwide neuromuscular disease clinic. “First is for education of patients and their families. Many of them are interested in knowing where very recent work stands.”

The second goal, Flanigan said, is to provide information for primary care physicians, pediatricians and other medical personnel who are often asked about neuromuscular disease, yet do not have access to the latest literature.

Flanigan says he plans to invite researchers from all over the globe to participate and, despite the series title, discussions will cover the entire field of neuromuscular disease research, not just muscular dystrophy.


In the first podcast, Mendell, who is co-director of the MDA clinic at Nationwide, discussed his recent investigation into using a gene for the protein follistatin to increase muscle size and strength. The findings were published in Science Translational Medicine in November 2009. (See “Follistatin Genes Strengthen Muscles in Monkeys.”)

Jerry Mendell

Mendell and his team discovered that the naturally-occurring follistatin protein produced a marked and durable increase in muscle size and strength, with no adverse effects, when injected into the leg muscles of monkeys. Follistatin works by blocking the action of myostatin, another naturally-occurring protein that retards muscle growth.

The findings have implications for people with muscle-wasting diseases like muscular dystrophy, as well as those with muscle damage due to other illnesses, injury or aging.

The second podcast addressed a potentially even more significant finding in gene therapy for SMA. Brian Kaspar and his team at Nationwide were able to restore near-normal muscle function in mice that had an SMA-like condition by injecting them at birth with a protein that is deficient in this disease. The findings were published in Nature Biotechnology on February 28, 2010. (See “Gene Therapy Rescues Mice with SMA.”)

Brian Kaspar

Kaspar’s research found that, if the protein injections were done a day or two after birth, the mice’s functioning was restored, but at just ten days after birth, the treatment didn’t work. The findings point out the potential need for newborn screening for SMA, in order to begin treatment as soon as possible.

Although both of the therapies discussed in the podcasts have potential for success in neuromuscular disease, more studies will need to be done before they are approved for human use.

To download or listen to the podcasts, go to www.nationwidechildrens.org/muscular-dystrophy-podcast.

For more information, links to abstracts of the journal articles, as well as links to the researchers’ lab pages, please visit the Nationwide clinic’s website.

Your rating: None Average: 4 (1 vote)
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or email publications@mdausa.org. See comment policy